tiprankstipranks

Insmed assumed with an Overweight at Morgan Stanley

Morgan Stanley analyst Maxwell Skor assumed coverage of Insmed (INSM) with an Overweight rating and $90 price target The firm views Insmed as well-positioned to drive meaningful value creation this year through the potential approval and launch in bronchiectasis, as well as data readouts from TPIP and brensocatib, says the analyst, who also notes that Q4 marked Arikayce’s “highest quarterly sales ever.”

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue